Equities Analysts Set Expectations for SRTS FY2024 Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Research analysts at Roth Capital lifted their FY2024 earnings estimates for shares of Sensus Healthcare in a research report issued on Thursday, November 14th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $0.40 per share for the year, up from their previous estimate of $0.36. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.09 EPS, Q1 2025 earnings at $0.16 EPS and Q2 2025 earnings at $0.19 EPS.

Several other equities research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Sensus Healthcare in a research note on Monday, August 12th. Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday.

Sensus Healthcare Stock Up 4.8 %

SRTS opened at $7.64 on Monday. The firm has a market cap of $125.22 million, a price-to-earnings ratio of 13.40 and a beta of 1.04. The company’s 50-day moving average price is $6.37 and its 200 day moving average price is $5.95. Sensus Healthcare has a fifty-two week low of $2.02 and a fifty-two week high of $8.29.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC bought a new position in shares of Sensus Healthcare in the third quarter valued at about $32,000. Chapin Davis Inc. acquired a new stake in Sensus Healthcare in the second quarter worth $53,000. Geode Capital Management LLC grew its position in shares of Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares during the period. Sachetta LLC boosted its position in Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after acquiring an additional 13,544 shares during the last quarter. Finally, XTX Topco Ltd grew its position in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares in the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.